Navigation Links
Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer
Date:8/31/2010

SAN FRANCISCO, Aug. 31 /PRNewswire/ -- Deloitte Recap recently presented the Allicense 2010 Breakthrough Alliance Award to pharmaceutical giant, Sanofi-aventis, and biotechnology firm, Exelixis, in recognition of their potential $1 billion alliance in which Exelixis gave Sanofi-aventis worldwide exclusive licenses for two early-stage cancer treatments and a stake in the development of PI3K inhibitor programs.  In exchange, Sanofi-aventis provided Exelixis an upfront payment of $140 million with an additional guaranteed $21 million over the next three years for research and development and could total up to $1 billion in milestone payments.

The annual award, presented at the Deloitte Recap Allicense conference, honors the efforts of business development licensing professionals.  Deloitte Recap analysts examined hundreds of biotech/big pharma deals signed in the previous year to identify the top five contenders for the deal of the year.  Business development licensing professionals throughout the industry voted to identify a winner.  

"Combining the research innovation of the biotech companies with the resources of global pharmaceutical corporations is essential to continued productivity in the life sciences industry," said Mark Edwards, managing director of Deloitte Recap LLC.

"Sanofi-aventis is extremely honored to have received the Allicense 2010 Deal of the Year Award for the Exelixis transaction," said Philippe Goupit, vice president of corporate licenses at Sanofi-aventis.  "This transaction perfectly reflects our new strategy to engage true collaborative partnerships with highly reputable innovative biotech companies such as Exelixis.  There is a lot to get out from such innovative types of collaboration for the ultimate benefit of patients."

Exelixis also was honored to win the Breakthrough Alliance Award in 2010 and 2009.  "We are very excited to receive the Allicense deal award for a second year in a row.  Over the years we worked very hard to create innovative deals that are examples for the industry," said Frances K. Heller, executive vice president for business development at Exelixis.  "Partnering has been a critical part of Exelixis' strategy and a key source of our non-dilutive financing.
Given the challenging economic environment, we believe partnering will continue to be an important source of funding for the industry."

The other deal finalists identified by Deloitte Recap were AstraZeneca/Targacept - Phase II Collaboration for Depression; Takeda/Amylin - Phase II Collaboration in Diabetes/Obesity; Millennium/Seattle Genetics - Phase II Co-Development for Lymphoma Product; and Novartis/Incyte - Phase III Collaboration for Cancer Products.

The Breakthrough Alliance Award deals were analyzed using the currently available deal data from the Recap IQ Series by Deloitte™. Some common elements to the deals include:

  • Large upfront cash and/or equity payments
  • Shared costs limits
  • Clear allocation of decision-making power
  • Shared commercial rights

  • About Deloitte RecapDeloitte Recap LLC was originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area. In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC (Recap). As used in this document, "Deloitte Recap" means Deloitte Recap LLC and "Deloitte" means Deloitte LLP and Deloitte Services LP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.Contact:Marykate ReesePublic RelationsDeloitte+1 203 257 0452mareese@deloitte.com
    '/>"/>

    SOURCE Deloitte
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloittes 2008 Washington State Technology Fast 50 for 5th Time in Past 7 Years
    2. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
    3. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
    4. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
    5. Sinovac Named to Deloitte Technology Fast 50 China
    6. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
    7. Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report
    8. Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List
    9. Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools
    10. Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year
    11. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/24/2017)... LANSING, Mich. , Jan. 24, 2017  Neogen ... it had terminated its agreement with SenesTech Incorporated (NASDAQ: ... marketing of a rodenticide being developed by SenesTech. The ... to the time when the SenesTech product was approved ... final EPA approval provided that the product could only ...
    (Date:1/24/2017)... WAYNE, Pa. , Jan. 24, 2017   ... services provider, today announced the addition of Jennifer ... new Senior Vice President and General Manager for the ... be responsible for Bracket,s work in Rater Training, Quality ... joins Bracket with a strong skillset and demonstrated record ...
    (Date:1/24/2017)... ... January 24, 2017 , ... Amendia, Inc., designer, ... Steven F. McAllister as Executive Vice President and Chief Financial Officer. , Steve ... international markets. Beginning his career at Howmedica, Inc., he has since served in ...
    (Date:1/24/2017)... MINNEAPOLIS (PRWEB) , ... January 24, 2017 , ... ... Tech’s decision to upgrade its Nor-Tech cluster with user-friendly bootable Intel KNL. ... processor, which is integrated into Nor-Tech’s demo cluster. The demo cluster is a ...
    Breaking Biology Technology:
    (Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
    (Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
    (Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
    Breaking Biology News(10 mins):